You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
首日上市破發!藥明巨諾-B(2126.HK)半日收跌6.09%
格隆匯 11-03 12:03
格隆匯11月3日丨CAR-T重磅玩家藥明巨諾-B(2126.HK)今日首日上市早盤一度衝高漲8.19%報25.75港元,隨後跳水走低,截至半日收盤跌6.09%報22.35港元,成交9.06億港元,換手率17.19%,最新總市值49億港元。該股此次IPO價格為23.8港元,淨籌21.967億港元。藥明巨諾是中國領先的細胞治療公司,主打候選產品relma-cel是一款針對復發或難治B細胞淋巴瘤的自體抗CD19 CAR-T產品。藥明巨諾在招股書中表示,倘若能按目前預計的時間獲批在中國上市,預計relma-cel將成為中國首個獲批一類生物製品CAR-T療法。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account